Featured News

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

People with celiac disease have a 10-fold greater risk for inflammatory bowel disease (IBD). Those with IBD have a 4-fold greater risk for celiac disease. A new study reviews the link between these two autoimmune disorders.

TAK-062, an orally administered synthetic enzyme that survives the acidity of the stomach and digests gluten effectively, has passed its phase 1 clinical drug trial, indicating it is safe to use in celiac patients.

Showcasing the “brightest ideas and breakthroughs in digestive disease,” DDW 2020 includes recent studies and innovations in celiac disease and gluten-related disorders, some of which we have curated and summarized for you.

A small pilot study suggests chemical pollutants might be an environmental factor associated with celiac disease in children. This is the first research to link the autoimmune disorder with persistent organic pollutants (POPs) detected in blood samples from celiac patients.

The first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.

The Celiac Disease Foundation uses peer-reviewed research to push our federal government to act responsibly. Our sponsorship of Columbia University’s Biennial Symposium, where the world’s expert celiac researchers share their findings and collaborate on future projects, continues this work.

Data from the Nexvax2 study shows celiac patients exposed to gluten react within two hours and experience nausea and vomiting, not the classic lower digestive symptoms commonly associated with celiac disease.

Even in the midst of the COVID-19 pandemic, celiac disease patients need treatments and a cure. On March 8, the Celiac Disease Foundation sponsored the First SSCD Consensus Workshop: Research Opportunities in Celiac Disease 2020 to inform NIH funding needs.